By Fineline Cube 
Zhejiang Medicine Co., Ltd. (SHA: 600216), a China-based pharmaceutical company, announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase 1 clinical trial for its Category 1 drug, XC2309 injection. The trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, and bioavailability of XC2309 in healthy adults following single and multiple doses.
XC2309: Targeted Treatment for Gastrointestinal Ulcer Bleeding
XC2309 injection is developed for the treatment of gastrointestinal ulcer bleeding caused by various conditions. Unlike existing oral medications such as vonoprazan, keverprazan, and tegoprazan, XC2309 offers a promising injectable treatment option, potentially expanding therapeutic choices for patients suffering from gastrointestinal ulcer bleeding.-Fineline Info & Tech